Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis-Reference-Cited by-同舟云学术

Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis

Published:2021-10-25 Issue:10 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Kanie Takayoshi¹,Mizuno Atsushi¹²³⁴,Takaoka Yoshimitsu¹,Suzuki Takahiro¹,Yoneoka Daisuke⁵,Nishikawa Yuri⁶⁷,Tam Wilson Wai San⁸,Morze Jakub⁹,Rynkiewicz Andrzej¹⁰,Xin Yiqiao¹¹,Wu Olivia¹¹,Providencia Rui¹²,Kwong Joey SW¹³

Affiliation:

1. Department of Cardiology; St. Luke's International Hospital; Tokyo Japan

2. Penn Medicine Nudge Unit; University of Pennsylvania Philadelphia; Philadelphia PA USA

3. Leonard Davis Institute for Health Economics; University of Pennsylvania; Philadelphia PA USA

4. Division of Cardiovascular Medicine; Hospital of the University of Pennsylvania; Philadelphia PA USA

5. Division of Biostatistics and Bioinformatics, Graduate School of Public Health; St. Luke’s International University; Tokyo Japan

6. Department of Gerontological Nursing and Healthcare Systems Management, Graduate School of Health Care Sciences; Tokyo Medical and Dental University; Tokyo Japan

7. Department of Gerontological Nursing; Kyorin University; Tokyo Japan

8. Alice Lee Center for Nursing Studies; NUS Yong Loo Lin School of Medicine; Singapore Singapore

9. Department of Human Nutrition; University of Warmia and Mazury; Olsztyn Poland

10. Department of Cardiology and Cardiosurgery; School of Medicine, University of Warmia and Mazury; Olsztyn Poland

11. Health Economics and Health Technology Assessment (HEHTA), Institute of Health and Wellbeing; University of Glasgow; Glasgow UK

12. Barts Heart Centre; St Bartholomew's Hospital, Barts Health NHS Trust; London UK

13. Global Health Nursing, Graduate School of Nursing Science; St. Luke's International University; Tokyo Japan

Publisher

Wiley

Subject

Pharmacology (medical)

Reference459 articles.

1. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure;Arturi;Endocrine,2017

2. Sotagliflozin In patients with diabetes and recent worsening heart failure;Bhatt;New England Journal of Medicine,2021

3. Effect of sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure (SOLOIST-WHF trial) Available from clinicaltrials.gov/ct2/show/NCT03521934

4. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV);Cannon;American Heart Journal,2018

5. Design and baseline characteristics of the evaluation of ertuglifozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV);Cannon;Journals of the American College of Cardiology,2018

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid;Acta Dermato-Venereologica;2024-09-04

2. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study;PLOS ONE;2024-08-08

3. The benefits of oral glucose-lowering agents: GLP-1 receptor agonists, DPP-4 and SGLT-2 inhibitors on myocardial ischaemia/reperfusion injury;European Journal of Pharmacology;2024-08

4. Incretin mimetics and acute pancreatitis: enemy or innocent bystander?;Current Opinion in Gastroenterology;2024-07-04

5. Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database;Diabetes Therapy;2024-07-03